Opinion|Videos|August 30, 2024
Future Considerations for Pneumococcal Vaccination
The key opinion leaders examine the recent approval of PCV21, assessing its potential influence on pneumococcal vaccination strategies, while also identifying and discussing current unmet needs in the field of pneumococcal vaccination.
Advertisement
Episodes in this series
- How will the recent approval of PCV21 impact pneumococcal vaccination decision making?
- What are the current unmet needs in the field of pneumococcal vaccination?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
2
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
3
Intensive BP Control Cuts CV Risk Regardless of CKD Status
4
Inside the New Consensus Recommendations for Acute Stroke Care
5